US Patent

US9604990 — Crystalline forms of pemetrexed diacid and manufacturing processes therefor

Composition of Matter · Assigned to Scinopharm Taiwan Ltd · Expires 2035-10-28 · 9y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects crystalline forms of pemetrexed diacid, specifically Forms 1 and 2, and methods for manufacturing them.

USPTO Abstract

Crystalline forms of pemetrexed diacid are provided (Forms 1 and 2) which are readily produced for either laboratory-scale or industrial scale. Processes for the preparation of Forms 1 and 2 are also provided.

Drugs covered by this patent

chembl-chembl225072 (PEMETREXED)

Patent Metadata

Patent number: US9604990
Jurisdiction: US
Classification: Composition of Matter
Expires: 2035-10-28
Drug substance claim: Yes
Drug product claim: No
Assignee: Scinopharm Taiwan Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.